Literature DB >> 19922990

ABC transporter gene expression in benign and malignant ovarian tissue.

Veronika Auner1, Jalid Sehouli, Gülten Oskay-Oezcelik, Reinhard Horvat, Paul Speiser, Robert Zeillinger.   

Abstract

OBJECTIVE: ATP-binding Cassette (ABC) transporters are thought to cause multiple drug resistance (MDR) in various carcinomas. Gene expression data from individual transporters in ovarian cancer tissue is contradictory and also scarce for some of them. RNA levels of a panel of ABC transporters were collected and analyzed to get a more detailed overview which transporters are of importance in resistance to chemotherapeutic agents in ovarian carcinoma.
METHODS: Real-time PCR was used to determine RNA expression levels of 9 ABC transporters in 50 benign tissue samples and 50 recurrent ovarian cancer samples. Genes exhibiting a significant difference between those two groups were further evaluated in 50 primary cancer samples. Data were analyzed with receiver operating characteristic (ROC) curves and multiple Wilcoxon-Mann-Whitney U-tests with Shaffer correction.
RESULTS: Gene expression of four transporters (ABCC1, ABCC2, ABCC3, and ABCB3) was significantly elevated in recurrent cancer lesions compared to benign tissue. Expression levels of these 4 ABC transporters were further analyzed in primary ovarian cancer lesions. A significant difference between primary and recurrent tumor tissue was found in all four genes. Changes in gene expression between benign samples and primary lesions were minor and not relevant.
CONCLUSIONS: Four of the examined ABC transporters are likely to play a role in the MDR of ovarian carcinoma. Gene expression of these transporters seems only up regulated through chemotherapy. The thesis that MDR in ovarian cancer is acquired through therapy itself and not present ab initio is supported by these findings. Copyright (c) 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19922990     DOI: 10.1016/j.ygyno.2009.10.077

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  25 in total

1.  A functional SNP in the 3'-UTR of TAP2 gene interacts with microRNA hsa-miR-1270 to suppress the gene expression.

Authors:  Bridgett Knox; Yong Wang; Lora J Rogers; Jiekun Xuan; Dianke Yu; Huaijin Guan; Jiwei Chen; Tieliu Shi; Baitang Ning; Susan A Kadlubar
Journal:  Environ Mol Mutagen       Date:  2017-12-05       Impact factor: 3.216

2.  Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.

Authors:  Chunqiao Tian; Christine B Ambrosone; Kathleen M Darcy; Thomas C Krivak; Deborah K Armstrong; Michael A Bookman; Warren Davis; Hua Zhao; Kirsten Moysich; Holly Gallion; Julie A DeLoia
Journal:  Gynecol Oncol       Date:  2011-11-21       Impact factor: 5.482

Review 3.  Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis.

Authors:  Sabita N Saldanha; Trygve O Tollefsbol
Journal:  J Cell Physiol       Date:  2014-04       Impact factor: 6.384

4.  EZH2-Mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells.

Authors:  Xingyue Zong; Weini Wang; Ali Ozes; Fang Fang; George E Sandusky; Kenneth P Nephew
Journal:  Cancer Res       Date:  2020-08-19       Impact factor: 12.701

5.  Proteomic and Bioinformatic Studies for the Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian Cancer.

Authors:  Leda Severi; Lorena Losi; Sergio Fonda; Laura Taddia; Gaia Gozzi; Gaetano Marverti; Fulvio Magni; Clizia Chinello; Martina Stella; Jalid Sheouli; Elena I Braicu; Filippo Genovese; Angela Lauriola; Chiara Marraccini; Alessandra Gualandi; Domenico D'Arca; Stefania Ferrari; Maria P Costi
Journal:  Front Pharmacol       Date:  2018-05-08       Impact factor: 5.810

6.  Prognostic Value of Two Polymorphisms, rs1045642 and rs1128503, in ABCB1 Following Taxane-based Chemotherapy: A Meta-Analysis.

Authors:  Quanyao Chen; Wanlong Lin; Jianhui Yang; Min Lin; Xiuxian Lin; Yiyin Weng; Yao Chen
Journal:  Asian Pac J Cancer Prev       Date:  2021-01-01

7.  Chemotherapy-induced hyaluronan production: a novel chemoresistance mechanism in ovarian cancer.

Authors:  Carmela Ricciardelli; Miranda P Ween; Noor A Lokman; Izza A Tan; Carmen E Pyragius; Martin K Oehler
Journal:  BMC Cancer       Date:  2013-10-14       Impact factor: 4.430

Review 8.  The Role of Eukaryotic and Prokaryotic ABC Transporter Family in Failure of Chemotherapy.

Authors:  Raafat El-Awady; Ekram Saleh; Amna Hashim; Nehal Soliman; Alaa Dallah; Azza Elrasheed; Ghada Elakraa
Journal:  Front Pharmacol       Date:  2017-01-10       Impact factor: 5.810

9.  CD44+ cancer stem-like cells in EBV-associated nasopharyngeal carcinoma.

Authors:  Samantha Wei-Man Lun; Siu Tim Cheung; Phyllis Fung Yi Cheung; Ka-Fai To; John Kong-Sang Woo; Kwong-Wai Choy; Chit Chow; Chartia Ching-Mei Cheung; Grace Tin-Yun Chung; Alice Suk-Hang Cheng; Chun-Wai Ko; Sai-Wah Tsao; Pierre Busson; Margaret Heung-Ling Ng; Kwok-Wai Lo
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

10.  Gene Expression Profiling Reveals Novel Candidate Markers of Ovarian Carcinoma Intraperitoneal Metastasis.

Authors:  Katerina Elsnerova; Alena Bartakova; Josef Tihlarik; Jiri Bouda; Lukas Rob; Petr Skapa; Martin Hruda; Ivan Gut; Beatrice Mohelnikova-Duchonova; Pavel Soucek; Radka Vaclavikova
Journal:  J Cancer       Date:  2017-10-09       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.